In a retrospective study analyzing 108 GBM patients, an intratumoral subregion both with high T1 contrast enhancement and low ADC, named “high risk volume (HRV)”, was identified on multi-parametric MRI, predicting both unmethylated MGMT status and shorter survival (p < 0.001 and p = 0.038, respectively, in the discovery and validation cohort) [133]. This evidence concerns the gene MGMT and glioblastoma.